Biotie Therapies Oyj

Type: Company
Name: Biotie Therapies Oyj (Biotie Therapies Corp)
First reported 22 hours ago - Updated 16 hours ago - 2 reports

Biotie Therapies updates outlook on Tozadenant and SYN120

Biotie Therapies Oyj:Says updates outlook on Tozadenant and SYN120.Says Tozadenant to advance into phase 3 in Parkinson's disease within Biotie's portfolio.Says considers Tozadenant to potentially be its most valuable asset.Evaluates options, which may ... [Published Reuters - 16 hours ago]
First reported 22 hours ago - Updated 22 hours ago - 1 reports

BRIEF-Biotie Therapies reports Q2 net loss of EUR 3.7 mln

7:39am BSTJuly 30 (Reuters) - Biotie Therapies Oyj : * Says Q2 revenue EUR 0.8 million versus EUR 2.1 million * Says for remainder of 2014 expects further revenue from Selincro, bothmilestones and royalties * Says Q2 net loss EUR 3.7 million versus loss ... [Published Reuters UK - 22 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Change in the number of votes relating to Bioti...

Change in the number of votes relating to Biotie Therapies Corp.'s shares ... [Published MoneyAM - 23 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Change in the number of votes relating to Biotie Therapies Corp.'s shares

at 8.40 a.m. The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the ... [Published Benzinga.com - 23 hours ago]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Change in the number of votes relating to Biotie Therapies Corp.'s shares

at 8.45 am Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 2 January 2014, pursuant to the Stock Option Plan 2011 and the Equity Incentive Plan 2011 (the "Plans") as follows:Under ... [Published Benzinga.com - 23 hours ago]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

BRIEF-Biotie Therapies clinical study with BTT1023 awarded external grant funding

Biotie Therapies Oyj :* Says clinical study with Biotie's BTT1023 in primarysclerosing cholangitisawarded external grant funding * Says the study will be conducted in the UK and is expected to startrecruiting patients by the end of 2014. * Says to be ... [Published Reuters - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 4 reports

Clinical study with Biotie's BTT1023 in primary...

Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding ... [Published MoneyAM - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 2 reports

BRIEF-Biotie Therapies Oyj - Selincro enters the market in Spain

7:06am BSTJuly 22 (Reuters) - Biotie Therapies Oyj : * Its partner H.Lundbeck A/S brought Selincro on the market in Spain * Says is eligible for a milestone payment of EUR 2 million related to themarket entry * Source text for Eikon * Further company ... [Published Reuters UK - Jul 22 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 4 reports

Biotie Therapies Selects Bracket's CDR System for Phase II Parkinson's Trial

Bracket announced that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected its CDR System for use as the primary endpoint for their Phase II trial of SYN120, an orally ... [Published Applied Clinical Trials - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

Michael J. Fox Foundation Awards Biotie $2M

Biotie Therapies has signed a $2M research contract with The Michael J. Fox Foundation to investigate SYN120 in Parkinson's disease patients with dementia. ... [Published Technology Networks - Jul 14 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 6 reports

Neurelis reclaims rights to epilepsy drug from Biotie

Encinitas-based Neurelis Inc. entered an agreement with Biotie Therapies Corp. to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development of intranasal diazepam (NRL-1) for pediatric and adult ... [Published San Diego Daily Transcript - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 3 reports

Biotie: Selincro receives positive draft guidan...

Biotie: Selincro receives positive draft guidance from UK's NICE ... [Published MoneyAM - Jul 10 2014]

Quotes

...in the various dementias, and also to serve as an instrument to definitively measure the benefits of treatment, " said Professor Keith Wesnes. "I'm delighted that Biotie has selected the CDR System for this very important trial."
Biotie Therapies Selects Bracket "s CDR System(TM) for Phase 2 Trial of Treatment of ParkinsonParkinson s Disease"
Sponsored by: "Parkinson's Disease affects over one million families and when I developed the CDR System over 20 years ago, it was with the intention of making a real impact in drug development, and eventually, in people's lives" said Professor Keith Wesnes. "I'm very pleased that Biotie has selected the CDR System for this very important trial."
Timo Veromaa, president and chief executive of Biotie, said: "Following the return of full global rights of tozadenant to Biotie in March 2014 we have now decided not to pursue further development of NRL-1 and wish Neurelis success with this important product. Biotie remains committed to starting Phase III with tozadenant in Parkinson's disease in the first half of 2015, and we look forward to the start of Phase II studies for SYN120 in Parkinson's disease dementia and BTT-1023 for primary sclerosing cholangitis by the end of 2014, and delivering top-line data from the ongoing Phase II study with nepicastat in cocaine dependence, also around end 2014."

More Content

All (75) | News (47) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1) | Press Releases (24)
sort by: Date | Relevance
UCB's (UCBJF) CEO Roch Doliveux on Q2 2014 Resu... [Published Seeking Alpha - 12 hours ago]
Biotie Therapies updates outlook on Tozadenant ... [Published Reuters - 16 hours ago]
BRIEF-Biotie Therapies reports Q2 net loss of E... [Published Reuters UK - 22 hours ago]
BRIEF-Biotie Therapies Oyj updates outlook on T... [Published Reuters UK - 22 hours ago]
Change in the number of votes relating to Bioti... [Published GlobeNewswire: Advertising News - 23 hours ago]
Biotie updates outlook on tozadenant and SYN120 [Published GlobeNewswire: Advertising News - 23 hours ago]
Biotie interim report 1 January - 30 June 2014 [Published GlobeNewswire: Advertising News - 23 hours ago]
Change in the number of votes relating to Bioti... [Published MoneyAM - 23 hours ago]
Change in the number of votes relating to Bioti... [Published Benzinga.com - 23 hours ago]
Change in the number of votes relating to Bioti... [Published Benzinga.com - 23 hours ago]
Change in the number of votes relating to Bioti... [Published GlobeNewswire: Advertising News - 23 hours ago]
BRIEF-Biotie Therapies clinical study with BTT1... [Published Reuters - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published MoneyAM - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published GlobeNewswire: Advertising News - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published GlobeNewswire: Advertising News - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published KGO - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published Indianapolis Business Journal - Jul 24 2014]
Clinical study with Biotie's BTT1023 in primary... [Published Value Investing News - Jul 24 2014]
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Advertising News - Jul 22 2014]
BRIEF-Biotie Therapies Oyj - Selincro enters th... [Published Reuters UK - Jul 22 2014]
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Acquisitions News - Jul 22 2014]
Biotie: Selincro enters the market in Spain [Published Street Sweeper - Jul 22 2014]
Biotie Therapies Selects Bracket's CDR System(T... [Published Scottrade - Jul 18 2014]
Biotie Therapies Selects Bracket's CDR System f... [Published Applied Clinical Trials - Jul 16 2014]
Biotie Therapies Selects Bracket"s CDR System(T... [Published Presskontakt.se - Jul 16 2014]
Biotie Therapies Selects Bracket's CDR System™... [Published TickerTech.com - Jul 16 2014]
Biotie Therapies Selects Bracket's CDR System™ ... [Published PR Newswire: Health - Jul 16 2014]
Michael J. Fox Foundation Awards Biotie $2M [Published Technology Networks - Jul 14 2014]
Michael J Fox Foundation to finance Parkinson's... [Published Manufacturing Chemist - Jul 14 2014]
Biotie passes up on option to acquire Neurelis [Published Pharma Letter - Jul 14 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biotie Therapies Selects Bracket's CDR System™ ... [Published PR Newswire: Health - Jul 16 2014]
COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as ...
Neurelis Regains Rights to Intranasal Diazepam ... [Published PR Newswire: Health - Jul 11 2014]
SAN DIEGO, July 11, 2014 /PRNewswire/ -- Neurelis, Inc. ("Neurelis") today announced an agreement with Biotie Therapies Corp. ("Biotie") to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development ...
Research and Markets: Tozadenant by Biotie (Par... [Published Business Wire Health News - May 19 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3f224r/tozadenant) has announced the addition of the "Tozadenant (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. Tozadenant ...
1

Press Releases

sort by: Date | Relevance
Change in the number of votes relating to Bioti... [Published GlobeNewswire: Advertising News - 23 hours ago]
Biotie updates outlook on tozadenant and SYN120 [Published GlobeNewswire: Advertising News - 23 hours ago]
Biotie interim report 1 January - 30 June 2014 [Published GlobeNewswire: Advertising News - 23 hours ago]
Change in the number of votes relating to Bioti... [Published GlobeNewswire: Advertising News - 23 hours ago]
Clinical study with Biotie's BTT1023 in primary... [Published GlobeNewswire: Advertising News - Jul 24 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.